Is Ketamine a Hallucinogen or a Dissociative Drug?

Ketamine is formally classified as a dissociative anesthetic, not a classical hallucinogen, though the line between those categories is blurrier than most drug classification systems admit. It works through a fundamentally different brain mechanism than drugs like LSD or psilocybin, yet at certain doses it can produce vivid hallucinations alongside its signature feeling of detachment from the body and surroundings. Understanding why pharmacologists insist on the distinction, and where that distinction genuinely matters, requires looking past the labels.

Two Different Keys, Two Different Locks

The clearest reason ketamine gets its own category is that it acts on a completely different receptor system than classic hallucinogens. Drugs like psilocybin and LSD primarily activate serotonin receptors, particularly the 5-HT2A subtype, which triggers the perceptual distortions and altered sense of meaning that define a psychedelic trip. Ketamine does something else entirely: it blocks a type of glutamate receptor called the NMDA receptor. Glutamate is the brain’s main excitatory signaling molecule, and when ketamine sits in the NMDA channel, it disrupts how neurons talk to each other in ways that produce a feeling of disconnection from both the body and the environment.¹

This is why the word “dissociative” stuck. When Edward Domino ran the first human trials with ketamine in the 1960s, volunteers described feeling conscious but somehow removed from their own sensory experience. They were not seeing geometric patterns or experiencing synesthesia in the way LSD users described. They were experiencing a split between awareness and perception, as though the mind had floated free of the body. Domino coined the term “dissociative anesthetic” to capture that quality, and the label has held ever since.²

What Dissociation Feels Like Compared to Hallucination

In everyday conversation, people sometimes use “hallucination” as a catch-all for any unusual perceptual experience on a drug. Pharmacologically, the terms point to different phenomena. A hallucination is perceiving something that is not there: hearing a voice when no one is speaking, seeing a face form in a blank wall. Dissociation is a disturbance not in what you perceive but in how connected you feel to it. Your hand might look perfectly normal but feel as though it belongs to someone else. Sounds may reach you but seem muffled and distant, like they are arriving from another room.

Ketamine’s hallmark is this second category. At moderate doses, people commonly describe out-of-body sensations, time distortion, and a dreamlike quality where the world feels unreal but is not replaced by vivid new imagery. The recreational community has a term for the deeper end of this spectrum, the “K-hole,” which refers to a state of near-complete detachment from sensory input and motor control, sometimes accompanied by intense internal visions that can resemble hallucinations. The point where dissociation tips into hallucination is not always crisp, and that ambiguity is part of what makes the classification question interesting.

Dose Makes the Difference

One of the strongest arguments against treating “dissociative” and “hallucinogenic” as a hard either-or comes from dose-response research. At sub-anesthetic doses, around 0.3 mg/kg or less given intravenously, ketamine produces only mild psychomimetic symptoms along with physical effects like double vision and involuntary eye movements.³ At these lower doses, many people describe a pleasant sense of floating or mild detachment but nothing resembling a hallucination.

Ramp the dose up and the picture changes. A cross-sectional study examining different ketamine doses in surgical patients found that higher doses significantly increased both the type and severity of postoperative hallucinations, along with prolonged dissociative experiences.⁴ In other words, low-dose ketamine looks squarely dissociative, while high-dose ketamine starts producing effects that look hallucinogenic by any reasonable definition. Duration of administration also mattered: longer infusion times were associated with more intense hallucinatory experiences.

This dose-dependent spectrum is one reason why calling ketamine simply “a dissociative” can be misleading. The drug does not have a single experiential profile. It has a range, and where you land on that range depends heavily on how much you take and how fast it gets into your bloodstream.

How Ketamine and Classic Psychedelics Affect the Brain Differently

Even when ketamine produces experiences that subjectively overlap with a psychedelic trip, the underlying brain activity looks quite different. A study comparing the neural effects of ketamine and LSD using local field potential recordings in animals found that the two drugs create altered brain states through distinct mechanisms. Ketamine increased overall neuronal activity while reducing connectivity between brain regions. LSD also reduced connectivity, but without the same boost in raw neuronal firing.⁵

Think of it this way: both drugs scramble the brain’s normal communication patterns, but they scramble them differently. Ketamine seems to rev up individual neurons while cutting the lines between them, a pattern consistent with the experience of feeling alert but disconnected. Classic psychedelics loosen the connections without the same increase in raw activity, which may explain why their effects feel more like a reorganization of perception rather than a withdrawal from it.

When researchers look at which specific brain networks ketamine affects, the default mode network and the salience network come up repeatedly. A scoping review of clinical experiments found that ketamine’s effects on pain processing correlated with connectivity changes in these large-scale networks, and that baseline connectivity patterns in areas like the medial prefrontal cortex and precuneus could even predict how well a patient would respond to ketamine treatment.⁶ These are networks involved in self-referential thought and in deciding what is salient enough to pay attention to, which lines up neatly with the subjective experience of losing your usual sense of self and surroundings.

Brain Wave Signatures Under Ketamine

Beyond connectivity changes, ketamine leaves a distinctive fingerprint in the brain’s electrical rhythms. Recordings from the hippocampus of mice showed that ketamine enhances background and evoked power in the gamma frequency range while simultaneously decreasing what researchers call relative induced power.⁷ Gamma oscillations are thought to help bind sensory information into a unified perception, so disrupting them may explain why the world feels fragmented or unreal under ketamine’s influence.

Complementary work in rats found that ketamine’s effect on gamma power in the prefrontal cortex varied by dose, and that these changes correlated with disruptions to auditory sensory gating, the brain’s ability to filter out repetitive, unimportant sounds.⁸ Sensory gating failures are a feature of psychotic states and, to a lesser degree, dissociative experiences. When the brain stops filtering properly, irrelevant stimuli flood in and perception becomes chaotic. This mechanism may help explain why high-dose ketamine can tip from dissociation into something that feels frankly hallucinatory: the gating system breaks down enough that the brain starts generating perceptions with no external source.

The Two Mirror-Image Molecules

Ketamine as used in most clinical settings is actually a 50/50 mix of two mirror-image molecules, called enantiomers. The S-form, esketamine, is the one the FDA approved as a nasal spray for treatment-resistant depression. The R-form is arketamine. These two molecules are chemically identical except for their three-dimensional shape, and that seemingly small difference translates into real differences in both clinical effects and subjective experience.

Esketamine binds more tightly to the NMDA receptor, making it roughly three times stronger as a painkiller and about one and a half times more potent as an anesthetic compared to arketamine.⁹ But stronger NMDA blockade does not necessarily mean better antidepressant. Animal studies consistently show that arketamine, despite its weaker NMDA binding, produces more potent and longer-lasting antidepressant effects in rodent models. And the side-effect profile diverges too: arketamine causes fewer dissociative and psychotomimetic effects and appears to carry less abuse potential than either the racemic mixture or esketamine.¹⁰

This split is fascinating for the classification question. If the dissociative and hallucinatory properties track more closely with NMDA binding strength (as the esketamine data suggest), and the antidepressant effect tracks with something else (possibly BDNF-related neurotrophic pathways), then the drug’s therapeutic value and its mind-altering properties might be separable in principle. That has obvious implications for designing future treatments that preserve the benefits while minimizing the psychoactive experience.

Ketamine’s Antidepressant Effect and the Role of Dissociation

One of the more surprising questions in ketamine research is whether the dissociative experience itself is necessary for the antidepressant effect, or just an inconvenient side effect riding along. The answer remains unsettled, but some evidence points to the dissociation actually playing a role.

A secondary analysis of a randomized trial examined whether the intensity of dissociation during ketamine infusion predicted how much depression improved afterward. For patients with mild to moderate dissociation scores, each additional point on the dissociation scale corresponded to a half-point improvement on a standard depression rating at 24 hours. That relationship faded by 72 hours and was gone by a week.¹¹ A separate study found that a specific component of dissociation, depersonalization (the feeling of being detached from yourself), predicted greater antidepressant response across multiple studies and time points.¹²

These findings do not prove that dissociation causes the antidepressant improvement. They could both be downstream effects of the same NMDA blockade, traveling in parallel rather than one causing the other. But they do suggest that the two are linked in a way researchers have not yet fully untangled. The arketamine data mentioned earlier complicates the picture further, since arketamine appears to produce strong antidepressant effects with less dissociation in animals. Human trials of arketamine are still in relatively early stages, so whether this pattern holds in people remains to be seen.

How Ketamine Lifts Depression at the Molecular Level

The antidepressant mechanism itself appears to run through glutamate signaling rather than the serotonin pathways targeted by traditional antidepressants. When ketamine blocks NMDA receptors, it triggers a cascade that leads to increased release of BDNF (brain-derived neurotrophic factor), a protein that supports the growth and maintenance of synaptic connections. Most clinical studies measuring blood levels of BDNF in patients receiving intravenous ketamine have found an increase, though some studies have not replicated this finding.¹³

This mechanism has nothing obvious to do with the subjective dissociative or hallucinatory experience. A neuron does not need you to feel disconnected from your body in order to upregulate BDNF production. That disconnect between the molecular action and the perceptual experience is part of why researchers remain uncertain about whether the altered state of consciousness is medically necessary or incidental.

Does Ketamine Affect Dopamine?

One hypothesis that circulated for years was that ketamine’s rapid effects might partly involve the dopamine system, specifically the dopamine transporter. If ketamine altered dopamine reuptake the way stimulants or certain drugs of abuse do, that could explain both its mood-lifting properties and its potential for misuse. But when researchers tested this directly by giving sub-anesthetic S-ketamine to rats and measuring dopamine transporter binding, they found no effect.¹⁴ That does not rule out every possible interaction between ketamine and dopamine, since the drug could affect dopamine through indirect routes, but it does push back on the simplest version of the hypothesis.

This matters for the classification question because drugs that strongly activate dopamine signaling, like amphetamines, get grouped into yet another category (stimulants). Ketamine does not fit neatly there either. It remains pharmacologically most at home in the dissociative class, even as its effects occasionally overlap with hallucinogens, and even as its abuse potential raises questions that sound more like stimulant or opioid discussions.

What User Experience Reports Show

If the pharmacology draws a clear line between dissociatives and classic psychedelics, the subjective experience is muddier. An analysis of thousands of recreational drug experience reports, sorted by substance, found that ketamine, LSD, and psilocybin mushroom reports showed only small differences on measures of emotional language, analytical thinking, and language related to mystical or psychedelic experiences.¹⁵ In other words, when people write about what these drugs felt like, the descriptions end up surprisingly similar, even though the underlying pharmacology is doing very different things.

This finding highlights a tension that runs through the entire classification debate. Categories like “dissociative” and “hallucinogen” are built on mechanism of action, which makes sense for pharmacologists and clinicians. But from the user’s perspective, the experience of ketamine at a moderate-to-high dose can feel a lot like what people describe as a psychedelic experience: ego dissolution, a sense of cosmic significance, visual imagery, emotional catharsis. The mechanistic labels are real and useful, but they do not perfectly map onto the felt reality.

Why the Categories Get Tangled in Practice

Drug classification systems were never designed to be tidy. The same regulatory schedules that group ketamine as a Schedule III controlled substance in the United States put it alongside drugs like testosterone and certain barbiturates, substances with completely unrelated mechanisms and effects. Classification serves legal, clinical, and research purposes simultaneously, and no single scheme satisfies all three.

Within pharmacology, “dissociative” is a subcategory of the broader group sometimes called “hallucinogens” in older textbooks. Some classification systems treat dissociatives as their own class entirely, separate from serotonergic psychedelics and from deliriants (anticholinergic drugs like scopolamine that produce confused, often unpleasant hallucinations). Others lump everything that distorts perception under “hallucinogen” and subdivide from there. The answer to “Is ketamine a hallucinogen or a dissociative?” depends partly on which system you are using and how inclusive your definition of “hallucinogen” is.

For practical purposes, the most accurate answer is that ketamine is a dissociative anesthetic that can produce hallucinations, particularly at higher doses and with longer exposure times. It is not a classical hallucinogen in the way psilocybin or LSD are, because it works through an entirely different receptor system and its primary subjective effect is detachment rather than perceptual enhancement or distortion. But the boundaries between these experiences are softer than the pharmacological categories suggest, and a person given a high enough dose of ketamine may well report an experience indistinguishable from what they would call a hallucination.

Veterinary Origins and the Safety Profile That Made Ketamine Stick Around

Ketamine’s staying power in medicine comes largely from its unusual safety profile as an anesthetic. Unlike most general anesthetics, it does not suppress breathing or drop blood pressure, which made it valuable in emergency settings and on battlefields where monitoring equipment was limited. The same properties made it a workhorse in veterinary medicine, where patients range from cats to horses and precise airway management is not always possible.²

Its widespread veterinary use contributed to the “horse tranquilizer” label that still follows ketamine in popular culture. That label is not exactly wrong, but it misrepresents the drug’s significance. Ketamine appears on the World Health Organization’s List of Essential Medicines and is used in human operating rooms, emergency departments, and psychiatric clinics worldwide. Reducing it to a veterinary drug would be like calling penicillin a farm antibiotic because farmers use it on livestock. The drug’s ability to sit at the intersection of anesthesia, pain management, psychiatry, and yes, recreational psychoactive use, is precisely what makes its classification so contested and so interesting.